Skip to main content
Clinical Trials/CTRI/2019/11/022192
CTRI/2019/11/022192
Not yet recruiting
未知

A COMPARATIVE STUDY ON THE EFFICACY OF INTRALESIONAL MMR VACCINE AND INTRALESIONAL PURIFIED PROTEIN DERIVATIVE IN VERRUCA VULGARIS

SHUNMADHI0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Sponsor
SHUNMADHI
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
SHUNMADHI

Eligibility Criteria

Inclusion Criteria

  • 1\.30 patients aged 12\-25 years with verruca vulgaris(less than 20 in number) attending the Dermatology OPD during the study period.
  • 2\.Patient who has not undergone any prior systemic or topical treatment.
  • 3\.Those who are giving consent to participate in the study.
  • 4\.Those who are willing for follow up.

Exclusion Criteria

  • 1\.Prior known allergic response to MMR vaccine
  • 2\.Patients who received any other treatments for their warts before enrolment.
  • 3\.Patients with H/O asthma,allergic skin disorders, meningitis or convulsions
  • 4\. Patient with acute febrile illness or signs of any inflammation or infection.
  • 5\.Patients with Hepatitis B \& Hepatitis C infection
  • 6\. Patients with immunosuppression/ HIV Infection
  • 7\.Patients with anogenital warts
  • 8\.Patients with H/O TB
  • 9\.Induration measuring \< 5 mm at 48 hours of Tuberculin skin test and MMR skin test.

Outcomes

Primary Outcomes

Not specified

Similar Trials